Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

The promise of allosteric kinase inhibition

Neil P. Shah

Blood (2024) 144 (19): 1975–1976.

https://doi.org/10.1182/blood.2024026052

Published: 2024

Journal Articles

BCR :: ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B. Leske, Delphine Rea, Stacey Phan, Kaeli B. Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P. Jacobson, Neil P. Shah

Blood (2024) 144 (6): 639–645.

https://doi.org/10.1182/blood.2023022538

Published: 2024

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Outcomes of Adolescents and Young Adult Patients with Chronic Myeloid Leukemia in the Era of Second-Generation TKIs and Treatment-Free Remission

Kelly Schoenbeck, Anousheh Afjei, Neil P. Shah

Blood (2023) 142 (Supplement 1): 3173.

https://doi.org/10.1182/blood-2023-188395

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

BGS-2456 Is a Novel Potent Covalent Inhibitor of FLT3 That Highly Discriminates Against KIT and Is Not Toxic Toward Normal Hematopoiesis in Vitro

Ariel Leyte-Vidal, Stacey Phan, Prachi Khare, FeiFei Hu, Chao Zhang, Ping Cao, Neil P. Shah

Blood (2023) 142 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2023-173116

Published: 2023

Journal Articles

Select P-Loop Mutants in BCR::ABL1 Confer Moderate to High Degrees of Resistance to Asciminib

Ariel Monet Leyte-Vidal, Neil P. Shah

Blood (2022) 140 (Supplement 1): 9606–9607.

https://doi.org/10.1182/blood-2022-169828

Published: 2022

Journal Articles

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

Blood (2021) 138 (Supplement 1): 2550.

https://doi.org/10.1182/blood-2021-146175

Published: 2021

Journal Articles

Being Present-CML: A Distress Reduction Intervention for Patients with Chronic Myeloid Leukemia Taking Tyrosine Kinase Inhibitors

Kelly L. Schoenbeck, Anand Dhruva, Albert Lee, Neha G. Goyal, Adrienne K. Yang, Sa Ra Park, Catherine C. Smith, Neil P Shah, Chloe E. Atreya

Blood (2021) 138 (Supplement 1): 4051.

https://doi.org/10.1182/blood-2021-152076

Published: 2021

Journal Articles

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Kelly L. Schoenbeck, MD, Sirisha Tummala, MD, Rebecca L. Olin, MD, Neha G. Goyal, PhD, Anand Dhruva, MD, Lloyd E. Damon, MD, Aaron C. Logan, MDPhDMPhil, Catherine C. Smith, MD, Neil P. Shah, MDPhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-143303

Published: 2020

Journal Articles

Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic Phase

Kelly L. Schoenbeck, MD, Sirisha Tummala, MD, Neha G. Goyal, PhD, Catherine C. Smith, MD, Neil P. Shah, MDPhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142997

Published: 2020

Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-133922

Published: 2020

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2019) 134 (Supplement_1): 1264.

https://doi.org/10.1182/blood-2019-124685

Published: 2019

Journal Articles

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Massimo Breccia, MD, Jorge E. Cortes, MD, Neil P Shah, MD PhD, Giuseppe Saglio, MD, Antonio Jiménez-Velasco, MD, Philipp Le Coutre, MD, Alexander Brun, PharmD, Irene DeGutis, Sai Bathena, Oumar Sy, PhD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 4155.

https://doi.org/10.1182/blood-2019-121872

Published: 2019

Journal Articles

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, MD PhD, Antonio Jiménez-Velasco, MD, Sarah Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Yair Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin Regueira, MD, Jeffrey H. Lipton, MD PhD

Blood (2018) 132 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2018-99-116563

Published: 2018

Journal Articles

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Kotoko Yamatani, MD, Yoko Tabe, MD PhD, Kaori Saito, Haeun Yang, Yuko Murakami-Tonami, MD PhD, Koya Suzuki, PhD, Weiguo Zhang, MD PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Kaoru Mogushi, PhD, Masaki Hosoya, PhD, Shigeo Yamaguchi, MD PhD, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y. Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 3944.

https://doi.org/10.1182/blood-2018-99-109957

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Multiparameter Single Cell Analysis to Identify Immune Cell States That May Contribute to Successful Treatment Discontinuation in Patients with Chronic Myeloid Leukemia

Kibeom Jang, PhD, Neil P. Shah, MD PhD

Blood (2018) 132 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2018-99-119267

Published: 2018

NARROW

The promise of allosteric kinase inhibition

BCR :: ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Outcomes of Adolescents and Young Adult Patients with Chronic Myeloid Leukemia in the Era of Second-Generation TKIs and Treatment-Free Remission

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

BGS-2456 Is a Novel Potent Covalent Inhibitor of FLT3 That Highly Discriminates Against KIT and Is Not Toxic Toward Normal Hematopoiesis in Vitro

Select P-Loop Mutants in BCR::ABL1 Confer Moderate to High Degrees of Resistance to Asciminib

Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials

Being Present-CML: A Distress Reduction Intervention for Patients with Chronic Myeloid Leukemia Taking Tyrosine Kinase Inhibitors

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic Phase

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Multiparameter Single Cell Analysis to Identify Immune Cell States That May Contribute to Successful Treatment Discontinuation in Patients with Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only